Royalty Pharma Plc Stock Price History
RPRX Stock | USD 32.36 0.10 0.31% |
Below is the normalized historical share price chart for Royalty Pharma Plc extending back to June 16, 2020. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Royalty Pharma stands at 32.36, as last reported on the 17th of February 2025, with the highest price reaching 32.89 and the lowest price hitting 32.28 during the day.
If you're considering investing in Royalty Stock, it is important to understand the factors that can impact its price. Royalty Pharma appears to be very steady, given 3 months investment horizon. Royalty Pharma Plc maintains Sharpe Ratio (i.e., Efficiency) of 0.2, which implies the firm had a 0.2 % return per unit of risk over the last 3 months. We have found thirty technical indicators for Royalty Pharma Plc, which you can use to evaluate the volatility of the company. Please evaluate Royalty Pharma's Semi Deviation of 0.7097, coefficient of variation of 531.02, and Risk Adjusted Performance of 0.1396 to confirm if our risk estimates are consistent with your expectations.
At this time, Royalty Pharma's Total Stockholder Equity is fairly stable compared to the past year. Stock Based Compensation is likely to rise to about 2.4 M in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 418.8 M in 2025. . Price To Free Cash Flows Ratio is likely to rise to 4.33 in 2025, whereas Price To Sales Ratio is likely to drop 4.79 in 2025. Royalty Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 25th of March 1993 | 200 Day MA 27.6396 | 50 Day MA 28.3668 | Beta 0.489 |
Royalty |
Sharpe Ratio = 0.1995
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | RPRX | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
1.91 actual daily | 17 83% of assets are more volatile |
Expected Return
0.38 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
0.2 actual daily | 15 85% of assets perform better |
Based on monthly moving average Royalty Pharma is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Royalty Pharma by adding it to a well-diversified portfolio.
Price Book 2.0186 | Enterprise Value Ebitda 12.7633 | Price Sales 8.241 | Shares Float 372.9 M | Dividend Share 0.84 |
Royalty Pharma Stock Price History Chart
There are several ways to analyze Royalty Stock price data. The simplest method is using a basic Royalty candlestick price chart, which shows Royalty Pharma price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
Highest Price | February 13, 2025 | 32.46 |
Lowest Price | December 19, 2024 | 24.28 |
Royalty Pharma February 17, 2025 Stock Price Synopsis
Various analyses of Royalty Pharma's daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Royalty Stock. It can be used to describe the percentage change in the price of Royalty Pharma from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Royalty Stock.Royalty Pharma Price Daily Balance Of Power | (0.16) | |
Royalty Pharma Price Rate Of Daily Change | 1.00 | |
Royalty Pharma Price Action Indicator | (0.28) |
Royalty Pharma February 17, 2025 Stock Price Analysis
Royalty Stock Price History Data
The price series of Royalty Pharma for the period between Tue, Nov 19, 2024 and Mon, Feb 17, 2025 has a statistical range of 8.18 with a coefficient of variation of 9.98. The price distribution for the period has arithmetic mean of 27.82. The median price for the last 90 days is 26.34. The company completed stock split (1:4) on 15th of October 2010. Royalty Pharma Plc had dividends distributed to its stock-holders on 2025-02-21.Open | High | Low | Close | Volume | ||
02/17/2025 | 32.46 | 32.89 | 32.28 | 32.36 | ||
02/17/2025 | 32.46 | 32.89 | 32.28 | 32.36 | ||
02/14/2025 | 32.46 | 32.89 | 32.28 | 32.36 | 4,822,374 | |
02/13/2025 | 32.39 | 32.63 | 32.13 | 32.46 | 3,979,839 | |
02/12/2025 | 32.27 | 32.56 | 31.73 | 32.34 | 3,662,213 | |
02/11/2025 | 31.60 | 32.72 | 31.30 | 32.25 | 7,665,139 | |
02/10/2025 | 31.73 | 31.79 | 31.35 | 31.72 | 3,343,504 | |
02/07/2025 | 31.48 | 31.75 | 31.36 | 31.73 | 3,393,397 | |
02/06/2025 | 31.62 | 31.63 | 31.23 | 31.40 | 3,373,697 | |
02/05/2025 | 31.34 | 31.64 | 31.18 | 31.45 | 3,155,070 | |
02/04/2025 | 31.03 | 31.60 | 31.03 | 31.26 | 3,623,559 | |
02/03/2025 | 31.07 | 31.66 | 31.07 | 31.33 | 3,080,007 | |
01/31/2025 | 31.64 | 31.68 | 31.22 | 31.58 | 4,071,952 | |
01/30/2025 | 31.93 | 32.06 | 31.49 | 31.59 | 3,890,145 | |
01/29/2025 | 32.00 | 32.21 | 31.61 | 31.95 | 5,471,126 | |
01/28/2025 | 31.82 | 32.12 | 31.60 | 31.94 | 6,875,643 | |
01/27/2025 | 31.11 | 31.76 | 30.95 | 31.72 | 3,704,130 | |
01/24/2025 | 30.61 | 31.10 | 30.61 | 31.06 | 5,780,103 | |
01/23/2025 | 30.13 | 30.65 | 30.04 | 30.62 | 5,347,998 | |
01/22/2025 | 30.09 | 30.21 | 29.73 | 30.08 | 3,541,447 | |
01/21/2025 | 30.79 | 30.80 | 30.26 | 30.30 | 2,794,612 | |
01/17/2025 | 30.72 | 31.08 | 30.52 | 30.75 | 2,887,148 | |
01/16/2025 | 30.64 | 31.09 | 30.11 | 30.95 | 4,829,577 | |
01/15/2025 | 30.23 | 30.82 | 30.01 | 30.74 | 4,510,597 | |
01/14/2025 | 29.90 | 30.20 | 29.67 | 30.03 | 5,888,176 | |
01/13/2025 | 29.83 | 30.78 | 29.77 | 29.99 | 7,816,924 | |
01/10/2025 | 27.55 | 29.89 | 27.47 | 29.49 | 8,066,463 | |
01/08/2025 | 25.98 | 26.37 | 25.77 | 26.20 | 2,225,778 | |
01/07/2025 | 25.63 | 26.06 | 25.55 | 26.04 | 2,727,346 | |
01/06/2025 | 25.73 | 26.10 | 25.40 | 25.75 | 2,232,329 | |
01/03/2025 | 25.81 | 25.96 | 25.72 | 25.84 | 2,082,916 | |
01/02/2025 | 25.55 | 25.89 | 25.55 | 25.79 | 1,521,459 | |
12/31/2024 | 25.30 | 25.59 | 25.28 | 25.51 | 2,179,396 | |
12/30/2024 | 25.41 | 25.50 | 25.18 | 25.32 | 1,914,509 | |
12/27/2024 | 25.27 | 25.68 | 25.27 | 25.54 | 2,036,094 | |
12/26/2024 | 25.19 | 25.46 | 25.16 | 25.40 | 1,740,149 | |
12/24/2024 | 25.23 | 25.35 | 25.02 | 25.23 | 1,350,225 | |
12/23/2024 | 24.72 | 25.26 | 24.46 | 25.25 | 5,439,334 | |
12/20/2024 | 24.34 | 25.00 | 24.32 | 24.92 | 7,574,662 | |
12/19/2024 | 24.24 | 24.48 | 24.05 | 24.28 | 4,359,724 | |
12/18/2024 | 25.09 | 25.27 | 24.46 | 24.47 | 3,737,456 | |
12/17/2024 | 25.06 | 25.27 | 24.80 | 25.12 | 3,046,241 | |
12/16/2024 | 24.75 | 25.28 | 24.70 | 25.00 | 4,385,627 | |
12/13/2024 | 25.17 | 25.17 | 24.73 | 24.84 | 2,540,924 | |
12/12/2024 | 25.11 | 25.42 | 25.10 | 25.21 | 2,891,122 | |
12/11/2024 | 25.43 | 25.50 | 25.02 | 25.20 | 2,851,459 | |
12/10/2024 | 26.05 | 26.05 | 25.46 | 25.59 | 3,130,284 | |
12/09/2024 | 25.81 | 26.22 | 25.62 | 26.01 | 2,588,855 | |
12/06/2024 | 26.42 | 26.59 | 25.87 | 25.91 | 4,327,547 | |
12/05/2024 | 26.10 | 26.54 | 26.10 | 26.39 | 2,390,475 | |
12/04/2024 | 26.24 | 26.36 | 25.94 | 26.10 | 2,973,111 | |
12/03/2024 | 26.32 | 26.47 | 26.15 | 26.34 | 3,191,202 | |
12/02/2024 | 26.52 | 26.60 | 26.29 | 26.43 | 2,113,638 | |
11/29/2024 | 26.60 | 26.66 | 26.46 | 26.66 | 1,411,354 | |
11/27/2024 | 26.35 | 26.65 | 26.23 | 26.60 | 1,811,787 | |
11/26/2024 | 26.59 | 26.62 | 26.02 | 26.29 | 1,991,661 | |
11/25/2024 | 26.46 | 26.83 | 26.41 | 26.47 | 6,834,103 | |
11/22/2024 | 26.38 | 26.63 | 26.33 | 26.43 | 2,461,722 | |
11/21/2024 | 26.26 | 26.67 | 26.23 | 26.40 | 4,329,564 | |
11/20/2024 | 26.09 | 26.29 | 25.80 | 26.22 | 2,006,893 | |
11/19/2024 | 25.63 | 26.03 | 25.47 | 26.01 | 7,299,478 |
About Royalty Pharma Stock history
Royalty Pharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Royalty is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Royalty Pharma Plc will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Royalty Pharma stock prices may prove useful in developing a viable investing in Royalty Pharma
Last Reported | Projected for Next Year | ||
Common Stock Shares Outstanding | 592.7 M | 418.8 M | |
Net Income Applicable To Common Shares | 49.3 M | 46.8 M |
Royalty Pharma Quarterly Net Working Capital |
|
Royalty Pharma Stock Technical Analysis
Royalty Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
All Next | Launch Module |
Royalty Pharma Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Royalty Pharma's price direction in advance. Along with the technical and fundamental analysis of Royalty Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Royalty to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | 0.1396 | |||
Jensen Alpha | 0.3391 | |||
Total Risk Alpha | 0.3358 | |||
Sortino Ratio | 0.3129 | |||
Treynor Ratio | (0.98) |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.